Wall Street's major market indices have kicked off the holiday-shortened trading week on a negative note as investors ready themselves for the 2025 trading year.
Synopsys (SNPS) is likely to win approval from the European Union for its $35B acquisition of Ansys (ANSS) based on the sale of two assets. Read for more.
Traws Pharma (TRAW) stock rocketed 260% after the company announced progress in developing its influenza treatment tivoxavir marboxil for the treatment of H5N1 bird flu.